Antiverse
Antiverse is a techbio company employing a machine-learning-centered approach to design antibodies for challenging targets like GPCRs and ion channels. Its platform uses target-specific libraries to enhance predictive accuracy, accelerating the antibody discovery process to six months and bringing needed therapies to patients faster. This approach addresses the limited number of existing GPCR-targeting antibodies despite their importance in drug development.
Buy Funded Startups lists
Funding Round: Seed
Funding Amount: $4.6M
Date: 15-Oct-2024
Investors: i&i Biotech Fund I (i&i Bio), Kadmos Capital, InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, AngelHub
Markets: Biotechnology, Pharmaceuticals, AI, Machine Learning, Drug Discovery, Other Healthcare Technology Systems, Big Data, LOHAS & Wellness, HealthTech, Life Sciences
HQ: Cardiff, Wales, United Kingdom
Founded: 2017
Website: https://www.antiverse.io/
LinkedIn: https://www.linkedin.com/company/antiverse
Twitter: https://twitter.com/AntiverseHQ
Crunchbase: https://www.crunchbase.com/organization/antiverse
Leave a Comment
Comments
No comments yet.